SIK1 couples LKB1 to p53-dependent anoikis and suppresses metastasis

Science Signaling

Volumn 2, Issue 80, 2009, Pages

  Cheng, Hailing ^a,b   Liu, Pixu ^a,b   Wang, Zhigang C ^a,c   Zou, Lihua ^a,c   Santiago, Stephanie ^a,b   Garbitt, Victoria ^a,b   Gjoerup, Ole V ^d   Dirk Iglehart, J ^a,c   Miron, Alexander ^a,c   Richardson, Andrea L ^a,c   Hahn, William C ^a,b,e   Zhao, Jean J ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^e BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIGEL; PROTEIN KINASE LKB1; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; SALT INDUCIBLE KINASE 1; UNCLASSIFIED DRUG; SNF1LK PROTEIN, HUMAN; STK11 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANOIKIS; ARTICLE; BREAST CANCER; CELL FUNCTION; CELL GROWTH; DISTANT METASTASIS; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; LUNG METASTASIS; METASTASIS; MICROMETASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC MUTATION; SURVIVAL; ANIMAL; BREAST TUMOR; FEMALE; METABOLISM; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANOIKIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70349565231     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2000369     Document Type: Article

References (72)

1. L. J. van 't Veer, H. Dai, M. J. van de Vijver, Y. D. He, A. A. Hart, M. Mao, H. L. Peterse, K. van der Kooy, M. J. Marton, A. T. Witteveen, G. J. Schreiber, R. M. Kerkhoven, C. Roberts, P. S. Linsley, R. Bernards, S. H. Friend, Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530-536 (2002).
2. O. Schmidt-Kittler, T. Ragg, A. Daskalakis, M. Granzow, A. Ahr, T. J. Blankenstein, M. Kaufmann, J. Diebold, H. Arnholdt, P. Muller, J. Bischoff, D. Harich, G. Schlimok, G. Riethmuller, R. Eils, C. A. Klein, From latent disseminated cells to overt metastasis: Genetic analysis of systemic breast cancer progression. Proc. Natl. Acad. Sci. U.S.A. 100, 7737-7742 (2003).
3. Y. Hüsemann, J. B. Geigl, F. Schubert, P. Musiani, M. Meyer, E. Burghart, G. Forni, R. Eils, T. Fehm, G. Riethmüller, C. A. Klein, Systemic spread is an early step in breast cancer. Cancer Cell 13, 58-68 (2008).
4. K. Podsypanina, Y. C. Du, M. Jechlinger, L. J. Beverly, D. Hambardzumyan, H. Varmus, Seeding and propagation of untransformed mouse mammary cells in the lung. Science 321, 1841-1844 (2008).
5. A. J. van de Wouw, R. L. Jansen, E. J. Speel, H. F. Hillen, The unknown biology of the unknown primary tumour: A literature review. Ann. Oncol. 14, 191-196 (2003).
6. E. Ruoslahti, J. C. Reed, Anchorage dependence, integrins, and apoptosis. Cell 77, 477-478 (1994).
7. S. M. Frisch, R. A. Screaton, Anoikis mechanisms. Curr. Opin. Cell Biol. 13, 555-562 (2001).
8. J. Grossmann, Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis 7, 247-260 (2002).
9. A. P. Gilmore, Anoikis. Cell Death Differ. 12 (Suppl. 2), 1473-1477 (2005).
10. P. Mehlen, A. Puisieux, Metastasis: A question of life or death. Nat. Rev. Cancer 6, 449-458 (2006).
11. M. J. van Nimwegen, B. van de Water, Focal adhesion kinase: A potential target in cancer therapy. Biochem. Pharmacol. 73, 597-609 (2007).
12. L. M. Shaw, I. Rabinovitz, H. H. Wang, A. Toker, A. M. Mercurio, Activation of phosphoinositide 3-OH kinase by the a6b4 integrin promotes carcinoma invasion. Cell 91, 949-960 (1997).
13. G. Dufour, M. J. Demers, D. Gagné, A. B. Dydensborg, I. C. Teller, V. Bouchard, I. Degongre, J. F. Beaulieu, J. Q. Cheng, N. Fujita, T. Tsuruo, K. Vallée, P. H. Vachon, Human intestinal epithelial cell survival and anoikis. Differentiation state-distinct regulation and roles of protein kinase B/Akt isoforms. J. Biol. Chem. 279, 44113-44122 (2004).
14. S. Douma, T. Van Laar, J. Zevenhoven, R. Meuwissen, E. Van Garderen, D. S. Peeper, Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430, 1034-1039 (2004).
15. K. H. Vousden, X. Lu, Live or let die: The cell's response to p53. Nat. Rev. Cancer 2, 594-604 (2002).
16. R. G. Jones, D. R. Plas, S. Kubek, M. Buzzai, J. Mu, Y. Xu, M. J. Birnbaum, C. B. Thompson, AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283-293 (2005).
17. C. H. Lee, K. Inoki, M. Karbowniczek, E. Petroulakis, N. Sonenberg, E. P. Henske, K. L. Guan, Constitutive mTOR activation in TSC mutants sensitizes cells to energy starvation and genomic damage via p53. EMBO J. 26, 4812-4823 (2007).
18. J. M. Lizcano, O. Göransson, R. Toth, M. Deak, N. A. Morrice, J. Boudeau, S. A. Hawley, L. Udd, T. P. Mäkelä, D. G. Hardie, D. R. Alessi, LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J. 23, 833-843 (2004).
19. A. Hemminki, D. Markie, I. Tomlinson, E. Avizienyte, S. Roth, A. Loukola, G. Bignell, W. Warren, M. Aminoff, P. Höglund, H. Järvinen, P. Kristo, K. Pelin, M. Ridanpää, R. Salovaara, T. Toro, W. Bodmer, S. Olschwang, A. S. Olsen, M. R. Stratton, A. de la Chapelle, L. A. Aaltonen, A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184-187 (1998).
20. Z. Shen, X. F. Wen, F. Lan, Z. Z. Shen, Z. M. Shao, The tumor suppressor gene LKB1 is associated with prognosis in human breast carcinoma. Clin. Cancer Res. 8, 2085-2090 (2002).
21. Z. G. Zhuang, G. H. Di, Z. Z. Shen, J. Ding, Z. M. Shao, Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential. Mol. Cancer Res. 4, 843-849 (2006). (Pubitemid 44877014)
22. M. Sanchez-Cespedes, P. Parrella, M. Esteller, S. Nomoto, B. Trink, J. M. Engles, W. H. Westra, J. G. Herman, D. Sidransky, Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res. 62, 3659-3662 (2002).
23. H. Ji, M. R. Ramsey, D. N. Hayes, C. Fan, K. McNamara, P. Kozlowski, C. Torrice, M. C. Wu, T. Shimamura, S. A. Perera, M. C. Liang, D. Cai, G. N. Naumov, L. Bao, C. M. Contreras, D. Li, L. Chen, J. Krishnamurthy, J. Koivunen, L. R. Chirieac, R. F. Padera, R. T. Bronson, N. I. Lindeman, D. C. Christiani, X. Lin, G. I. Shapiro, P. A. Jänne, B. E. Johnson, M. Meyerson, D. J. Kwiatkowski, D. H. Castrillon, N. Bardeesy, N. E. Sharpless, K. K. Wong, LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807-810 (2007).
24. D. R. Alessi, K. Sakamoto, J. R. Bayascas, LKB1-dependent signaling pathways. Annu. Rev. Biochem. 75, 137-163 (2006).
25. D. Ilić, E. A. Almeida, D. D. Schlaepfer, P. Dazin, S. Aizawa, C. H. Damsky, Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53- mediated apoptosis. J. Cell Biol. 143, 547-560 (1998).
26. R. E. Bachelder, M. J. Ribick, A. Marchetti, R. Falcioni, S. Soddu, K. R. Davis, A. M. Mercurio, p53 inhibits a6b4 integrin survival signaling by promoting the caspase 3-dependent cleavage of AKT/PKB. J. Cell Biol. 147, 1063-1072 (1999).
27. M. Vitale, T. Di Matola, M. Bifulco, A. Casamassima, G. Fenzi, G. Rossi, Apoptosis induced by denied adhesion to extracellular matrix (anoikis) in thyroid epithelial cells is p53 dependent but fails to correlate with modulation of p53 expression. FEBS Lett. 462, 57-60 (1999).
28. D. Ravid, S. Maor, H. Werner, M. Liscovitch, Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-I receptors and signaling. Oncogene 24, 1338-1347 (2005).
29. B. C. Lewis, D. S. Klimstra, N. D. Socci, S. Xu, J. A. Koutcher, H. E. Varmus, The absence of p53 promotes metastasis in a novel somatic mouse model for hepatocellular carcinoma. Mol. Cell. Biol. 25, 1228-1237 (2005).
30. P. W. Derksen, X. Liu, F. Saridin, H. van der Gulden, J. Zevenhoven, B. Evers, J. R. van Beijnum, A. W. Griffioen, J. Vink, P. Krimpenfort, J. L. Peterse, R. D. Cardiff, A. Berns, J. Jonkers, Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10, 437-449 (2006).
31. J. J. Zhao, Z. Liu, L. Wang, E. Shin, M. F. Loda, T. M. Roberts, The oncogenic properties of mutant p110a and p110b phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 102, 18443-18448 (2005).
32. J. J. Zhao, O. V. Gjoerup, R. R. Subramanian, Y. Cheng, W. Chen, T. M. Roberts, W. C. Hahn, Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell 3, 483-495 (2003).
33. S. R. Romanov, B. K. Kozakiewicz, C. R. Holst, M. R. Stampfer, L. M. Haupt, T. D. Tlsty, Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 409, 633-637 (2001).
34. J. Wang, G. J. Hannon, D. H. Beach, Risky immortalization by telomerase. Nature 405, 755-756 (2000).
35. T. Utermark, B. S. Schaffhausen, T. M. Roberts, J. J. Zhao, The p110a isoform of phosphatidylinositol 3-kinase is essential for polyomavirus middle T antigen-mediated transformation. J. Virol. 81, 7069-7076 (2007).
36. J. S. Boehm, J. J. Zhao, J. Yao, S. Y. Kim, R. Firestein, I. F. Dunn, S. K. Sjostrom, L. A. Garraway, S. Weremowicz, A. L. Richardson, H. Greulich, C. J. Stewart, L. A. Mulvey, R. R. Shen, L. Ambrogio, T. Hirozane-Kishikawa, D. E. Hill, M. Vidal, M. Meyerson, J. K. Grenier, G. Hinkle, D. E. Root, T. M. Roberts, E. S. Lander, K. Polyak, W. C. Hahn, Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 129, 1065-1079 (2007).
37. H. Xia, H. Qi, Y. Li, J. Pei, J. Barton, M. Blackstad, T. Xu, W. Tao, LATS1 tumor suppressor regulates G2/M transition and apoptosis. Oncogene 21, 1233-1241 (2002).
38. Y. Liu, D. M. Templeton, Cadmium activates CaMK-II and initiates CaMK-IIdependent apoptosis in mesangial cells. FEBS Lett. 581, 1481-1486 (2007).
39. T. Miyazaki, M. Shen, D. Fujikura, N. Tosa, H. R. Kim, S. Kon, T. Uede, J. C. Reed, Functional role of death-associated protein 3 (DAP3) in anoikis. J. Biol. Chem. 279, 44667-44672 (2004).
40. H. Sanjo, T. Kawai, S. Akira, DRAKs, novel serine/threonine kinases related to deathassociated protein kinase that trigger apoptosis. J. Biol. Chem. 273, 29066-29071 (1998).
41. S. Wang, M. Guo, H. Ouyang, X. Li, C. Cordon-Cardo, A. Kurimasa, D. J. Chen, Z. Fuks, C. C. Ling, G. C. Li, The catalytic subunit of DNA-dependent protein kinase selectively regulates p53-dependent apoptosis but not cell-cycle arrest. Proc. Natl. Acad. Sci. U.S.A. 97, 1584-1588 (2000).
42. E. Shaulian, A. Zauberman, D. Ginsberg, M. Oren, Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequencespecific DNA binding. Mol. Cell. Biol. 12, 5581-5592 (1992).
43. Y. Zhang, H. Lu, P. Dazin, Y. Kapila, Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: Fibronectin and integrin av mediate survival signals through focal adhesion kinase. J. Biol. Chem. 279, 48342-48349 (2004).
44. B. Vogelstein, D. Lane, A. J. Levine, Surfing the p53 network. Nature 408, 307-310 (2000).
45. J. Doi, H. Takemori, X. Z. Lin, N. Horike, Y. Katoh, M. Okamoto, Salt-inducible kinase represses cAMP-dependent protein kinase-mediated activation of human cholesterol side chain cleavage cytochrome P450 promoter through the CREB basic leucine zipper domain. J. Biol. Chem. 277, 15629-15637 (2002).
46. Y. Ariumi, A. Kaida, J. Y. Lin, M. Hirota, O. Masui, S. Yamaoka, Y. Taya, K. Shimotohno, HTLV-1 tax oncoprotein represses the p53-mediated trans-activation function through coactivator CBP sequestration. Oncogene 19, 1491-1499 (2000).
47. F. Toledo, G. M. Wahl, Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6, 909-923 (2006).
48. K. Imamura, T. Ogura, A. Kishimoto, M. Kaminishi, H. Esumi, Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-b-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 287, 562-567 (2001).
49. C. M. Contreras, S. Gurumurthy, J. M. Haynie, L. J. Shirley, E. A. Akbay, S. N. Wingo, J. O. Schorge, R. R. Broaddus, K. K. Wong, N. Bardeesy, D. H. Castrillon, Loss of Lkb1 provokes highly invasive endometrial adenocarcinomas. Cancer Res. 68, 759-766 (2008).
50. N. Bardeesy, M. Sinha, A. F. Hezel, S. Signoretti, N. A. Hathaway, N. E. Sharpless, M. Loda, D. R. Carrasco, R. A. DePinho, Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature 419, 162-167 (2002).
51. P. Karuman, O. Gozani, R. D. Odze, X. C. Zhou, H. Zhu, R. Shaw, T. P. Brien, C. D. Bozzuto, D. Ooi, L. C. Cantley, J. Yuan, The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol. Cell 7, 1307-1319 (2001).
52. S. Bamford, E. Dawson, S. Forbes, J. Clements, R. Pettett, A. Dogan, A. Flanagan, J. Teague, P. A. Futreal, M. R. Stratton, R. Wooster, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 91, 355-358 (2004).
53. A. L. Richardson, Z. C. Wang, A. De Nicolo, X. Lu, M. Brown, A. Miron, X. Liao, J. D. Iglehart, D. M. Livingston, S. Ganesan, X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121-132 (2006).
54. K. Chin, S. DeVries, J. Fridlyand, P. T. Spellman, R. Roydasgupta, W. L. Kuo, A. Lapuk, R. M. Neve, Z. Qian, T. Ryder, F. Chen, H. Feiler, T. Tokuyasu, C. Kingsley, S. Dairkee, Z. Meng, K. Chew, D. Pinkel, A. Jain, B. M. Ljung, L. Esserman, D. G. Albertson, F. M. Waldman, J. W. Gray, Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell 10, 529-541 (2006).
55. X. Lu, X. Lu, Z. C. Wang, J. D. Iglehart, X. Zhang, A. L. Richardson, Predicting features of breast cancer with gene expression patterns. Breast Cancer Res. Treat. 108, 191-201 (2008).
56. Y. Wang, J. G. Klijn, Y. Zhang, A. M. Sieuwerts, M. P. Look, F. Yang, D. Talantov, M. Timmermans, M. E. Meijer-van Gelder, J. Yu, T. Jatkoe, E. M. Berns, D. Atkins, J. A. Foekens, Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
57. A. M. Davidoff, P. A. Humphrey, J. D. Iglehart, J. R. Marks, Genetic basis for p53 overexpression in human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 88, 5006-5010 (1991).
58. R. J. Shaw, N. Bardeesy, B. D. Manning, L. Lopez, M. Kosmatka, R. A. DePinho, L. C. Cantley, The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6, 91-99 (2004).
59. R. J. Shaw, M. Kosmatka, N. Bardeesy, R. L. Hurley, L. A. Witters, R. A. DePinho, L. C. Cantley, The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A. 101, 3329-3335 (2004).
60. M. Sjöström, K. Stenström, K. Eneling, J. Zwiller, A. I. Katz, H. Takemori, A. M. Bertorello, SIK1 is part of a cell sodium-sensing network that regulates active sodium transport through a calcium-dependent process. Proc. Natl. Acad. Sci. U.S.A. 104, 16922-16927 (2007).
61. S. H. Koo, L. Flechner, L. Qi, X. Zhang, R. A. Screaton, S. Jeffries, S. Hedrick, W. Xu, F. Boussouar, P. Brindle, H. Takemori, M. Montminy, The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109-1111 (2005).
62. R. Berdeaux, N. Goebel, L. Banaszynski, H. Takemori, T. Wandless, G. D. Shelton, M. Montminy, SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat. Med. 13, 597-603 (2007).
63. M. Kowanetz, P. Lönn, M. Vanlandewijck, K. Kowanetz, C. H. Heldin, A. Moustakas, TGFb induces SIK to negatively regulate type I receptor kinase signaling. J. Cell Biol. 182, 655-662 (2008).
64. E. Briasoulis, N. Pavlidis, Cancer of unknown primary origin. Oncologist 2, 142-152 (1997).
65. G. Ismael, E. de Azambuja, A. Awada, Molecular profiling of a tumor of unknown origin. N. Engl. J. Med. 355, 1071-1072 (2006).
66. J. Engel, R. Eckel, J. Kerr, M. Schmidt, G. Fürstenberger, R. Richter, H. Sauer, H. J. Senn, D. Hölzel, The process of metastasisation for breast cancer. Eur. J. Cancer 39, 1794 - 1806 (2003).
67. G. P. Gupta, D. X. Nguyen, A. C. Chiang, P. D. Bos, J. Y. Kim, C. Nadal, R. R. Gomis, K. Manova-Todorova, J. Massagué, Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446, 765-770 (2007).
68. D. X. Nguyen, J. Massagué, Genetic determinants of cancer metastasis. Nat. Rev. Genet. 8, 341-352 (2007).
69. J. Moffat, D. A. Grueneberg, X. Yang, S. Y. Kim, A. M. Kloepfer, G. Hinkle, B. Piqani, T. M. Eisenhaure, B. Luo, J. K. Grenier, A. E. Carpenter, S. Y. Foo, S. A. Stewart, B. R. Stockwell, N. Hacohen, W. C. Hahn, E. S. Lander, D. M. Sabatini, D. E. Root, A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298 (2006).
70. T. F. Westbrook, E. S. Martin, M. R. Schlabach, Y. Leng, A. C. Liang, B. Feng, J. J. Zhao, T. M. Roberts, G. Mandel, G. J. Hannon, R. A. Depinho, L. Chin, S. J. Elledge, A genetic screen for candidate tumor suppressors identifies REST. Cell 121, 837-848 (2005).
71. J. A. Parrott, E. Nilsson, R. Mosher, G. Magrane, D. Albertson, D. Pinkel, J. W. Gray, M. K. Skinner, Stromal-epithelial interactions in the progression of ovarian cancer: Influence and source of tumor stromal cells. Mol. Cell. Endocrinol. 175, 29-39 (2001).
72. We thank the Broad Institute RNAi Platform and D. Root for advice and reagents. This work was supported in part by grants from the Dana-Farber-Harvard National Cancer Institute Specialized Program of Research Excellence in Breast Cancer (J.D.I.), US Department of Defense Breast Cancer Research Program [W81XWH-07-1-0408) (W.C.H.) and BC051565 (J.J.Z.)], the Tisch Family Fund (W.C.H.), a Claudia Barr Award (J.J.Z.), and a Woman's Cancer Program Award (J.J.Z.). In compliance with Harvard Medical School guidelines, we disclose that W.C.H. and J.J.Z. are consultants for Novartis Pharmaceuticals, Inc.